2022 January 18
1.
The MICK (Mobile integrated cognitive kit) app: Digital rapid automatized naming for visual assessment across the spectrum of neurological disorders. Park G, Balcer MJ, Hasanaj L, Joseph B, Kenney R, Hudson T, Rizzo JR, Rucker JC, Galetta SL, Balcer LJ, Grossman SN.
J Neurol Sci. 2022 Jan 11;434:120150. doi: 10.1016/j.jns.2022.120150. Online ahead of print.
PMID: 35038658
2.
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Chen JJ, Sotirchos ES, Henderson AD, Vasileiou ES, Flanagan EP, Bhatti MT, Jamali S, Eggenberger ER, Dinome M, Frohman LP, Arnold AC, Bonelli L, Seleme N, Mejia-Vergara AJ, Moss HE, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Hellmann MA, Hodge D, Oertel FC, Paul F, Saidha S, Calabresi PA, Pittock SJ.
Mult Scler Relat Disord. 2022 Jan 11;58:103525. doi: 10.1016/j.msard.2022.103525. Online ahead of print.
PMID: 35038647
3.
Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J, Valdelvira ME, Giraldo AI, Paz-Rojas E, Gascón F, Santamaría A, Agüera E, Túnez I.
Mult Scler Relat Disord. 2022 Jan 11;58:103520. doi: 10.1016/j.msard.2022.103520. Online ahead of print.
PMID: 35038645
4.
Identifying Candidate Genes Associated with Sporadic Amyotrophic Lateral Sclerosis via Integrative Analysis of Transcriptome-Wide Association Study and Messenger RNA Expression Profile. Li P, Cheng S, Wen Y, Cheng B, Liu L, Wu X, Ao X, Huang Z, Liao C, Li S, Zhang F, Zhang Z.
Cell Mol Neurobiol. 2022 Jan 17. doi: 10.1007/s10571-021-01186-0. Online ahead of print.
PMID: 35038056
5.
The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Azadvari M, Mirmosayyeb O, Hosseini M, Vaheb S, Razavi SZE.
Neurol Sci. 2022 Jan 17. doi: 10.1007/s10072-022-05871-w. Online ahead of print.
PMID: 35038045
6.
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity. Alcalá C, Cubas L, Carratalá S, Gascón F, Quintanilla-Bordás C, Gil-Perotín S, Gorriz D, Pérez-Miralles F, Gasque R, Castillo J, Casanova B.
J Neurol. 2022 Jan 17. doi: 10.1007/s00415-021-10926-7. Online ahead of print.
PMID: 35038000
7.
Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review. Weld-Blundell IV, Grech L, Learmonth YC, Marck CH.
Acta Neurol Scand. 2022 Jan 17. doi: 10.1111/ane.13574. Online ahead of print.
PMID: 35037722 Review.
8.
Happy Anniversary: NARCOMS. Halper J.
Int J MS Care. 2021 Nov-Dec;23(6):iv. doi: 10.7224/1537-2073-23.6.ivb. Epub 2021 Dec 29.
PMID: 35035300 Free PMC article. No abstract available.
9.
Dual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for Ca2+ signaling during T cell activation. Gu F, Krüger A, Roggenkamp HG, Alpers R, Lodygin D, Jaquet V, Möckl F, Hernandez C LC, Winterberg K, Bauche A, Rosche A, Grasberger H, Kao JY, Schetelig D, Werner R, Schröder K, Carty M, Bowie AG, Huber S, Meier C, Mittrücker HW, Heeren J, Krause KH, Flügel A, Diercks BP, Guse AH.
Sci Signal. 2021 Nov 16;14(709):eabe3800. doi: 10.1126/scisignal.abe3800. Epub 2021 Nov 16.
PMID: 34784249
10.
TSC1 Suppresses Macrophage Necroptosis for the Control of Infection by Fungal Pathogen Candida albicans. Li T, Xie Y, Shi L, Sun Y, Wen J, Deng Z, Zhang H, Li H, Yang J, Xiao H.
Immunohorizons. 2021 Feb 17;5(2):90-101. doi: 10.4049/immunohorizons.2000093.
PMID: 33597177
2022 January 16
1.
Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis. Kim S, Lee EJ, Kim KW, Seo D, Moon S, Kim KK, Lim YM.
Mult Scler Relat Disord. 2022 Jan 5;58:103500. doi: 10.1016/j.msard.2022.103500. Online ahead of print.
PMID: 35032884
2.
Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina. Alonso R, Garcea O, Rojas JI, Alonso M, Lázaro L, López P, Casas M, Tkachuk V, Steinberg J, Barboza A, Martínez A, Ysrraelit C, Correale J, Marrodan M, Chertcoff A, Deri N, Miguez J, Patrucco L, Cristiano E, Pestchanker C, Silva E, Vrech C, Zanga G, Leguizamón F, Carnero Contentti E, Carra A, Mainella C, Silva BA.
Mult Scler Relat Disord. 2022 Jan 2;58:103483. doi: 10.1016/j.msard.2021.103483. Online ahead of print.
PMID: 35032883
3.
Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis. Huang WC, Lin HC, Yang YH, Hsu CW, Chen NC, Tsai WC, Cheng BC, Tsai NW.
Mult Scler Relat Disord. 2022 Jan 10;58:103514. doi: 10.1016/j.msard.2022.103514. Online ahead of print.
PMID: 35032880
4.
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, Amico E; Italian MS register.
Mult Scler Relat Disord. 2022 Jan 2;58:103489. doi: 10.1016/j.msard.2022.103489. Online ahead of print.
PMID: 35032879
5.
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E.
Mult Scler Relat Disord. 2022 Jan 10;58:103486. doi: 10.1016/j.msard.2022.103486. Online ahead of print.
PMID: 35032878 Free PMC article.
6.
A comparison between subjective and objective measurements of spasticity in neuromyelitis optica spectrum disorder patients. Jinkarn N, Tisavipat N, Jitprapaikulsan J, Prayoonwiwat N, Rattanathamsakul N, Siritho S.
Mult Scler Relat Disord. 2022 Jan 10;58:103517. doi: 10.1016/j.msard.2022.103517. Online ahead of print.
PMID: 35032877
7.
Impact of intestinal disorders on central and peripheral nervous system diseases. El-Hakim Y, Bake S, Mani KK, Sohrabji F.
Neurobiol Dis. 2022 Jan 12:105627. doi: 10.1016/j.nbd.2022.105627. Online ahead of print.
PMID: 35032636
8.
Cannabidiol and substance use disorder: Dream or reality. Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer AF, Manzoni O, Haghparast A.
Neuropharmacology. 2022 Jan 12:108948. doi: 10.1016/j.neuropharm.2022.108948. Online ahead of print.
PMID: 35032495 Review.
9.
N6-methyladenosine and Neurological Diseases. Zhang N, Ding C, Zuo Y, Peng Y, Zuo L.
Mol Neurobiol. 2022 Jan 15. doi: 10.1007/s12035-022-02739-0. Online ahead of print.
PMID: 35032318 Review.
10.
Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis. Zhuang X, Hu X, Zhang S, Li X, Yuan X, Wu Y.
Clin Rev Allergy Immunol. 2022 Jan 15. doi: 10.1007/s12016-021-08892-z. Online ahead of print.
PMID: 35031958 Review.
11.
Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer’s Disease. Fagan SG, Bechet S, Dev KK.
Mol Neurobiol. 2022 Jan 15. doi: 10.1007/s12035-021-02613-5. Online ahead of print.
PMID: 35031916
12.
The effects of mesenchymal stem cells transplantation on A1 neurotoxic reactive astrocyte and demyelination in the cuprizone model. Barati S, Kashani IR, Tahmasebi F.
J Mol Histol. 2022 Jan 15. doi: 10.1007/s10735-021-10046-6. Online ahead of print.
PMID: 35031895
13.
Cortical morphology predicts placebo response in multiple sclerosis. Cherkasova MV, Fu JF, Jarrett M, Johnson P, Abel S, Tam R, Rauscher A, Sossi V, Kolind S, Li DKB, Sadovnick AD, Machan L, Girard JM, Emond F, Vosoughi R, Traboulsee A, Stoessl AJ.
Sci Rep. 2022 Jan 14;12(1):732. doi: 10.1038/s41598-021-04462-7.
PMID: 35031632
14.
Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial. Williams TE, Holdsworth KP, Nicholas JM, Eshaghi A, Katsanouli T, Wellington H, Heslegrave A, Zetterberg H, Frost C, Chataway J.
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 14;9(2):e1130. doi: 10.1212/NXI.0000000000001130. Print 2022 Mar.
PMID: 35031587
15.
Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination. Tiller C, Black L, Ponsonby AL, Taylor B, van der Mei I, Clarke MW; Ausimmune Investigator Group, Lucas RM.
J Steroid Biochem Mol Biol. 2022 Jan 11:106060. doi: 10.1016/j.jsbmb.2022.106060. Online ahead of print.
PMID: 35031430
16.
Assessment and Treatment of Nocturia in Neurological Disease in a Primary Care Setting: Systematic Review and Nominal Group Technique Consensus. van Merode NAM, Dawson S, Coulthard E, Henderson EJ, Rice CM, Rees J, Smith M, Strong E, Cotterill N, Huntley AL, Drake MJ.
Eur Urol Focus. 2022 Jan 11:S2405-4569(21)00323-0. doi: 10.1016/j.euf.2021.12.012. Online ahead of print.
PMID: 35031351 Review.
17.
Dietary interventions for multiple sclerosis-related outcomes: Summary of a cochrane review. Hartman LJ, Ne P, Cs JT, Vacchi L, Merdad R, Bc J.
Explore (NY). 2022 Jan 2:S1550-8307(21)00274-3. doi: 10.1016/j.explore.2021.12.007. Online ahead of print.
PMID: 35031230 No abstract available.
18.
(Cast2021) Oxygenated Hypothermic Machine Perfusion of Kidney Transplantation from Donors After Cardiac Death Due to Long-Term Low Blood Pressure and Hypoxia: The First Case Report of a Clinical Trial Using a New Japanese Perfusion System. Miyagi S, Kashiwadate T, Nishimaki H, Tokodai K, Fujio A, Miyazawa K, Sasaki K, Matsumura M, Unno M, Kamei T, Matsuno N.
Transplant Proc. 2022 Jan 11:S0041-1345(21)00916-7. doi: 10.1016/j.transproceed.2021.09.075. Online ahead of print.
PMID: 35031116
19.
The frequencies of peripheral blood CD5+CD19+ B cells, CD3–CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder. Khani L, Jazayeri MH, Nedaeinia R, Bozorgmehr M, Nabavi SM, Ferns GA.
Allergy Asthma Clin Immunol. 2022 Jan 14;18(1):5. doi: 10.1186/s13223-021-00596-5.
PMID: 35031055
2022 January 15
1.
Isolation of Transcriptomic-Quality Total RNA from Mouse Spinal Cords. Stokes JV, Nicaise AJ, Frodella CM, Varela-Stokes AS, Thompson T, Kaplan BLF.
Curr Protoc. 2022 Jan;2(1):e338. doi: 10.1002/cpz1.338.
PMID: 35030295
2.
Multiple sclerosis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. Sabatino JJ Jr, Mittl K, Rowles WM, McPolin K, Rajan JV, Laurie MT, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander JR, DeRisi JL, Hollenbach JA, Wilson MR, Zamvil SS, Bove R.
JCI Insight. 2022 Jan 14:e156978. doi: 10.1172/jci.insight.156978. Online ahead of print.
PMID: 35030101
3.
Disability and mortality in a cohort of MS patients: how the real-world scenario is changed. Bergamaschi R, Mallucci G, Fusco S, Montomoli C.
J Neurol. 2022 Jan 14. doi: 10.1007/s00415-021-10940-9. Online ahead of print.
PMID: 35029742 No abstract available.
4.
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. Tranfa M, Tortora M, Pontillo G, Iuzzolino V, Riccio E, Caccavallo S, Di Risi T, Monti S, Lanzillo R, Brescia Morra V, Palma G, Petracca M, Pisani A, Brunetti A, Cocozza S.
Eur Radiol. 2022 Jan 14. doi: 10.1007/s00330-021-08487-4. Online ahead of print.
PMID: 35029733
5.
Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients. Jasiak-Zatońska M, Michalak S, Osztynowicz K, Kozubski W, Kalinowska-Łyszczarz A.
Neurol Neurochir Pol. 2022 Jan 14. doi: 10.5603/PJNNS.a2022.0007. Online ahead of print.
PMID: 35029294
6.
RGMa regulates CCL5 expression via the BMP receptor in experimental autoimmune encephalomyelitis mice and endothelial cells. Tang S, Su B, Tao T, Yan W, Zhang R, Qin X, Feng J.
Mol Med Rep. 2022 Mar;25(3):85. doi: 10.3892/mmr.2022.12601. Epub 2022 Jan 14.
PMID: 35029290
7.
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis. Reynolds A, Gaughan M, Holden D, Redenbaugh V, Dunne J, Redmond J, Conlon N.
Ir J Med Sci. 2022 Jan 13. doi: 10.1007/s11845-021-02913-8. Online ahead of print.
PMID: 35028898
8.
Recent advances in preventing neurodegenerative diseases. Chou SC, Aggarwal A, Dawson VL, Dawson TM, Kam TI.
Fac Rev. 2021 Dec 1;10:81. doi: 10.12703/r/10-81. eCollection 2021.
PMID: 35028646 Free PMC article. Review.
9.
Early Impact of the COVID-19 Pandemic on Outpatient Neurologic Care in Hawai’i. Crocker J, Liu K, Smith M, Nakamoto M, Mitchell C, Zhu E, Ma E, Morden FT, Chong A, Van N, Dang N, Borman P, Carrazana E, Viereck J, Liow KK.
Hawaii J Health Soc Welf. 2022 Jan;81(1):6-12.
PMID: 35028589 Free PMC article.
10.
A Trigeminal Neuropathy From an Inactive Hepatocellular Carcinoma. Ram A, Paul R, Viswam V, Aravind B.
Cureus. 2021 Dec 10;13(12):e20340. doi: 10.7759/cureus.20340. eCollection 2021 Dec.
PMID: 35028229 Free PMC article.
2022 January 14
1.
Pre-analytical challenges for the quantification of endocannabinoids in human serum. Kratz D, Sens A, Schäfer SMG, Hahnefeld L, Geisslinger G, Thomas D, Gurke R.
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jan 7;1190:123102. doi: 10.1016/j.jchromb.2022.123102. Online ahead of print.
PMID: 35026652
2.
Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis. Ineichen BV, Tsagkas C, Absinta M, Reich DS.
Neuroimage Clin. 2022 Jan 10;33:102939. doi: 10.1016/j.nicl.2022.102939. Online ahead of print.
PMID: 35026625
3.
The burden of sepsis in critically ill patients with multiple sclerosis: A population-based cohort study. Oud L, Garza J.
J Crit Care. 2022 Jan 10;69:153985. doi: 10.1016/j.jcrc.2022.153985. Online ahead of print.
PMID: 35026610
4.
Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis. Ye F, Dai Y, Wang T, Liang J, Wu X, Lan K, Sheng W.
J Neuroimmunol. 2022 Jan 7;364:577809. doi: 10.1016/j.jneuroim.2022.577809. Online ahead of print.
PMID: 35026432
5.
Case-control study of adverse childhood experiences and multiple sclerosis risk and clinical outcomes. Horton MK, McCurdy S, Shao X, Bellesis K, Chinn T, Schaefer C, Barcellos LF.
PLoS One. 2022 Jan 13;17(1):e0262093. doi: 10.1371/journal.pone.0262093. eCollection 2022.
PMID: 35025951
6.
miR-27a-3p regulates expression of intercellular junctions at the brain endothelium and controls the endothelial barrier permeability. Harati R, Hammad S, Tlili A, Mahfood M, Mabondzo A, Hamoudi R.
PLoS One. 2022 Jan 13;17(1):e0262152. doi: 10.1371/journal.pone.0262152. eCollection 2022.
PMID: 35025943
7.
Epstein-Barr virus and multiple sclerosis. Robinson WH, Steinman L.
Science. 2022 Jan 13:eabm7930. doi: 10.1126/science.abm7930. Online ahead of print.
PMID: 35025606
8.
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A.
Science. 2022 Jan 21. doi: 10.1126/science.abj8222. Online ahead of print.
PMID: 35025605
9.
MAC2 is a long-lasting marker of peripheral cell infiltrates into the mouse CNS after bone marrow transplantation and coronavirus infection. Hohsfield LA, Tsourmas KI, Ghorbanian Y, Syage AR, Jin Kim S, Cheng Y, Furman S, Inlay MA, Lane TE, Green KN.
Glia. 2022 Jan 13. doi: 10.1002/glia.24144. Online ahead of print.
PMID: 35025109
10.
Aromatase in the Human Brain. Azcoitia I, Mendez P, Garcia-Segura LM.
Androg Clin Res Ther. 2021 Dec 23;2(1):189-202. doi: 10.1089/andro.2021.0007. eCollection 2021.
PMID: 35024691 Free PMC article. Review.
11.
Let’s talk about sex(ual) wellbeing! Staff perceptions of implementing a novel service for people with Multiple Sclerosis. Jarvis L, McConville K, Devereux S, O’Riordan J.
Mult Scler J Exp Transl Clin. 2022 Jan 6;8(1):20552173211072285. doi: 10.1177/20552173211072285. eCollection 2022 Jan-Mar.
PMID: 35024165 Free PMC article.
12.
Cervical Spinal Cord Atrophy can be Accurately Quantified Using Head Images. Taheri K, Vavasour IM, Abel S, Lee LE, Johnson P, Ristow S, Tam R, Laule C, Ackermans NC, Schabas A, Cross H, Chan JK, Sayao AL, Bhan V, Devonshire V, Carruthers R, Li DK, Traboulsee AL, Kolind SH, Dvorak AV.
Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211070760. doi: 10.1177/20552173211070760. eCollection 2022 Jan-Mar.
PMID: 35024164 Free PMC article.
13.
Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor. Chey SY, Kermode AG.
Mult Scler J Exp Transl Clin. 2022 Jan 5;8(1):20552173211070750. doi: 10.1177/20552173211070750. eCollection 2022 Jan-Mar.
PMID: 35024163 Free PMC article.
14.
Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis. Ajitomi S, Fujimori J, Nakashima I.
Mult Scler J Exp Transl Clin. 2022 Jan 5;8(1):20552173211070749. doi: 10.1177/20552173211070749. eCollection 2022 Jan-Mar.
PMID: 35024162 Free PMC article.
15.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I.
Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar.
PMID: 35024161 Free PMC article.
16.
Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL.
Mult Scler J Exp Transl Clin. 2022 Jan 5;8(1):20552173211069359. doi: 10.1177/20552173211069359. eCollection 2022 Jan-Mar.
PMID: 35024160 Free PMC article.
17.
Functional intermuscular reduction in spasticity for people with multiple sclerosis. Miller BJ, Kolobe TH, Larson RD, Pribble BA, Pardo G, James SA.
Mult Scler J Exp Transl Clin. 2022 Jan 5;8(1):20552173211061547. doi: 10.1177/20552173211061547. eCollection 2022 Jan-Mar.
PMID: 35024159 Free PMC article.
18.
Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. Villaverde-González R.
Degener Neurol Neuromuscul Dis. 2022 Jan 5;12:1-21. doi: 10.2147/DNND.S203406. eCollection 2022.
PMID: 35023987 Free PMC article. Review.
19.
The Molecular Mechanisms Through Which Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Myelin Regeneration. Clark KC, Wang D, Kumar P, Mor S, Kulubya E, Lazar SV, Wang A.
Adv Biol (Weinh). 2022 Jan 13:e2101099. doi: 10.1002/adbi.202101099. Online ahead of print.
PMID: 35023637 Review.
20.
Genetics and functional genomics of multiple sclerosis. Kim W, Patsopoulos NA.
Semin Immunopathol. 2022 Jan 12. doi: 10.1007/s00281-021-00907-3. Online ahead of print.
PMID: 35022889 Review.
21.
Hemispherectomy for hemimegalencephaly in a 6.5-week-old infant with tuberous sclerosis complex. Serletis D, MacDonald C, Xu Q, Kazina CJ, Dakshinamurti S, Marin S, Del Bigio MR.
Childs Nerv Syst. 2022 Jan 13. doi: 10.1007/s00381-021-05431-1. Online ahead of print.
PMID: 35022853
22.
Agreement of different OCT scan directions for individual retinal-layer thickness measurements in multiple sclerosis subjects with prior unilateral optic neuritis. Domínguez-Vicent A, Nilsson M, Brautaset R, Venkataraman AP.
Sci Rep. 2022 Jan 12;12(1):566. doi: 10.1038/s41598-021-04611-y.
PMID: 35022479
23.
Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. Jones BE, Maerz MD, Bahnson HT, Somasundaram A, McCarthy LH, Speake C, Buckner JH.
J Immunol. 2022 Jan 12:ji2100850. doi: 10.4049/jimmunol.2100850. Online ahead of print.
PMID: 35022272
24.
Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia. Barbieri MA, Bagnato G, Ioppolo C, Versace AG, Irrera N.
CNS Neurol Disord Drug Targets. 2022 Jan 11. doi: 10.2174/1871527321666220111124928. Online ahead of print.
PMID: 35021982
25.
TRPMS to improve voiding in patients with MS. Masone MC.
Nat Rev Urol. 2022 Jan;19(1):4. doi: 10.1038/s41585-021-00554-1.
PMID: 34887570 No abstract available.
26.
Δ9 -Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo. Huerga-Gómez A, Aguado T, Sánchez-de la Torre A, Bernal-Chico A, Matute C, Mato S, Guzmán M, Galve-Roperh I, Palazuelos J.
Glia. 2021 Mar;69(3):532-545. doi: 10.1002/glia.23911. Epub 2020 Sep 21.
PMID: 32956517 Free PMC article.
2022 January 13
1.
Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R.
Clin Exp Immunol. 2021 Nov 18:uxab015. doi: 10.1093/cei/uxab015. Online ahead of print.
PMID: 35020857
2.
Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes. Lang Y, Chu F, Liu L, Zheng C, Li C, Shen D, Liu S, Zhang W, Cui L, Zhu J.
Clin Exp Immunol. 2021 Nov 27:uxab022. doi: 10.1093/cei/uxab022. Online ahead of print.
PMID: 35020839
3.
Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age. Sarpong-Kumankomah S, Knox KB, Kelly ME, Hunter G, Popescu B, Nichol H, Kopciuk K, Ntanda H, Gailer J.
PLoS One. 2022 Jan 12;17(1):e0262160. doi: 10.1371/journal.pone.0262160. eCollection 2022.
PMID: 35020753
4.
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. Frahm N, Fneish F, Ellenberger D, Flachenecker P, Paul F, Warnke C, Kleinschnitz C, Parciak T, Krefting D, Hellwig K, Haas J, Rommer PS, Stahmann A, Zettl UK.
Neurol Ther. 2022 Jan 12. doi: 10.1007/s40120-021-00320-w. Online ahead of print.
PMID: 35020157
5.
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis. Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG.
Neurol Ther. 2022 Jan 12. doi: 10.1007/s40120-021-00319-3. Online ahead of print.
PMID: 35020156
6.
Assessment of Natural Language Processing Methods for Ascertaining the Expanded Disability Status Scale Score From the Electronic Health Records of Patients With Multiple Sclerosis: Algorithm Development and Validation Study. Yang Z, Pou-Prom C, Jones A, Banning M, Dai D, Mamdani M, Oh J, Antoniou T.
JMIR Med Inform. 2022 Jan 12;10(1):e25157. doi: 10.2196/25157.
PMID: 35019849
7.
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP.
Neurodegener Dis Manag. 2022 Jan 12. doi: 10.2217/nmt-2021-0041. Online ahead of print.
PMID: 35019731
8.
Characterization of Radioiodinated Diaryl Oxadiazole Derivatives as SPECT Probes for Detection of Myelin in Multiple Sclerosis. Watanabe H, Maekawa R, Iikuni S, Kakae M, Matsuo N, Shirakawa H, Kaneko S, Ono M.
ACS Chem Neurosci. 2022 Jan 12. doi: 10.1021/acschemneuro.1c00753. Online ahead of print.
PMID: 35019269
9.
Association between clinical evaluation and self perception of deglutition with motor disability scale in patients with multiple sclerosis. Piloti DTW, Ruiz VCD, Ribeiro MC, Almeida ST.
Codas. 2022 Jan 10;34(2):e20210026. doi: 10.1590/2317-1782/20212021026. eCollection 2022.
PMID: 35019079 English, Portuguese.
10.
Determinants of long-term opioid prescribing in an urban population- a cross sectional study. Naughton M, Redmond P, Durbaba S, Ashworth M, Molokhia M.
Br J Clin Pharmacol. 2022 Jan 11. doi: 10.1111/bcp.15231. Online ahead of print.
PMID: 35018644
11.
Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis. Tremolanti C, Cavallini C, Meyer L, Klein C, Da Pozzo E, Costa B, Germelli L, Taliani S, Patte-Mensah C, Mensah-Nyagan AG.
Mol Neurobiol. 2022 Jan 11. doi: 10.1007/s12035-022-02737-2. Online ahead of print.
PMID: 35018577
12.
Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID-19 era. Toscano S, Patti F, Chisari CG, Arena S, Finocchiaro C, Schillaci CE, Zappia M.
Neurol Sci. 2022 Jan 11:1-9. doi: 10.1007/s10072-022-05868-5. Online ahead of print.
PMID: 35018548 Free PMC article.
13.
Free-water diffusion tensor imaging detects occult periependymal abnormality in the AQP4-IgG-seropositive neuromyelitis optica spectrum disorder. Kim M, Choi KS, Hyun RC, Hwang I, Yun TJ, Kim SM, Kim JH.
Sci Rep. 2022 Jan 11;12(1):512. doi: 10.1038/s41598-021-04490-3.
PMID: 35017589
14.
Acute Disseminated Encephalomyelitis in FET PET/MR. Lohaus N, Mader C, Jelcic I, Reimann R, Huellner MW.
Clin Nucl Med. 2022 Feb 1;47(2):e137-e139. doi: 10.1097/RLU.00003879.
PMID: 34507326
15.
Exercise leads to metabolic changes associated with improved strength and fatigue in people with MS. Keller J, Zackowski K, Kim S, Chidobem I, Smith M, Farhadi F, Bhargava P.
Ann Clin Transl Neurol. 2021 Jun;8(6):1308-1317. doi: 10.1002/acn3.51368. Epub 2021 May 6.
PMID: 33955210 Free PMC article.
16.
Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways. Arnoriaga-Rodríguez M, Mayneris-Perxachs J, Contreras-
Gut. 2021 Dec;70(12):2283-2296. doi: 10.1136/gutjnl-2020-323371. Epub 2021 Jan 29.
PMID: 33514598 Free PMC article.
2022 January 12
1.
Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE; Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative.
Mult Scler Relat Disord. 2022 Jan 4;58:103482. doi: 10.1016/j.msard.2021.103482. Online ahead of print.
PMID: 35016114 Free PMC article.
2.
Pregnancy-induced brain MRI changes in women with multiple sclerosis. Uher T, Kubala Havrdova E, Vodehnalova K, Krasensky J, Capek V, Vaneckova M, Horakova D.
Eur J Neurol. 2022 Jan 11. doi: 10.1111/ene.15245. Online ahead of print.
PMID: 35015921
3.
Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological Involvement. Sharma S, Shen T, Chitranshi N, Gupta V, Basavarajappa D, Mirzaei M, You Y, Krezel W, Graham SL, Gupta V.
Mol Neurobiol. 2022 Jan 11. doi: 10.1007/s12035-021-02709-y. Online ahead of print.
PMID: 35015251 Review.
4.
Optimizing Readability and Format of Plain Language Summaries for Medical Research Articles: Cross-sectional Survey Study. Martínez Silvagnoli L, Shepherd C, Pritchett J, Gardner J.
J Med Internet Res. 2022 Jan 11;24(1):e22122. doi: 10.2196/22122.
PMID: 35014966
5.
High-resolution quantitative MRI of multiple sclerosis spinal cord lesions. McDowell AR, Petrova N, Carassiti D, Miquel ME, Thomas DL, Barker GJ, Schmierer K, Wood TC.
Magn Reson Med. 2022 Jan 11. doi: 10.1002/mrm.29152. Online ahead of print.
PMID: 35014736
6.
Pustular Psoriasis following treatment for Multiple Sclerosis. Couper C, Shaffrali F.
Clin Exp Dermatol. 2022 Jan 11. doi: 10.1111/ced.15100. Online ahead of print.
PMID: 35014707 No abstract available.
7.
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward. P Moss B, Miller DM.
Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668. Online ahead of print.
PMID: 35014561 No abstract available.
8.
Brain Homogenate Decoys for Antigen-Specific Cell Amplification. Griffin JD, Huayamares SG, Walston TR, Song JY, Shao M, Sedlacek AR, Diaz DL, Chakravarti AR, Berkland CJ.
ACS Appl Bio Mater. 2021 Jan 18;4(1):387-391. doi: 10.1021/acsabm.0c01048. Epub 2020 Dec 23.
PMID: 35014289
9.
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson B, Hains AB, Chen C, Galanter J, Burgess BL, Cho W, Kerchner GA, Yeh FL, Ghosh AS, Cheeti S, Brooks L, Honigberg L, Couch JA, Rothenberg ME, Brunstein F, Sharma KR, van den Berg L, Berry JD, Glass JD.
Ann Clin Transl Neurol. 2022 Jan 10. doi: 10.1002/acn3.51491. Online ahead of print.
PMID: 35014217
10.
Toe clearance facilitation to improve walking in multiple sclerosis: The effect of cyclical focal muscle vibration. Hardin EC, Bailey SN, Kobetic R, Lombardo LM, Foglyano KM, Schnellenberger JR, Selkirk SM.
PM R. 2022 Jan 10. doi: 10.1002/pmrj.12759. Online ahead of print.
PMID: 35014187 No abstract available.
11.
The surprising course of multiple sclerosis relapse in a patient after SARS-CoV-2 vaccination. Łagosz P, Biegus J, Gruszka E, Zymliński R.
Kardiol Pol. 2022 Jan 11. doi: 10.33963/KP.a2022.0005. Online ahead of print.
PMID: 35014011 No abstract available.
12.
Immunological causes of obsessive-compulsive disorder: is it time for the concept of an “autoimmune OCD” subtype? Endres D, Pollak TA, Bechter K, Denzel D, Pitsch K, Nickel K, Runge K, Pankratz B, Klatzmann D, Tamouza R, Mallet L, Leboyer M, Prüss H, Voderholzer U, Cunningham JL; ECNP Network Immuno-NeuroPsychiatry, Domschke K, Tebartz van Elst L, Schiele MA.
Transl Psychiatry. 2022 Jan 10;12(1):5. doi: 10.1038/s41398-021-01700-4.
PMID: 35013105 Review.
13.
Physiotherapists perceived role in managing anxiety in patients with relapsing-remitting multiple sclerosis: a mixed-methods study. Lucas L, Parker J.
Arch Physiother. 2022 Jan 11;12(1):2. doi: 10.1186/s40945-021-00124-z.
PMID: 35012683 Free PMC article.
14.
Potential Contribution of IL-27 and IL-23 Gene Polymorphisms to Multiple Sclerosis Susceptibility: An Association Analysis at Genotype and Haplotype Level. Barac IS, Iancu M, Văcăraș V, Cozma A, Negrean V, Sâmpelean D, Mureșanu DF, Procopciuc LM.
J Clin Med. 2021 Dec 22;11(1):37. doi: 10.3390/jcm11010037.
PMID: 35011777
15.
New Promising Therapeutic Avenues of Curcumin in Brain Diseases. Benameur T, Giacomucci G, Panaro MA, Ruggiero M, Trotta T, Monda V, Pizzolorusso I, Lofrumento DD, Porro C, Messina G.
Molecules. 2021 Dec 31;27(1):236. doi: 10.3390/molecules27010236.
PMID: 35011468 Free PMC article. Review.
16.
Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype. Almeida CF, Teixeira N, Correia-da-Silva G, Amaral C.
Molecules. 2021 Dec 28;27(1):156. doi: 10.3390/molecules27010156.
PMID: 35011388 Free PMC article. Review.
17.
Paratuberculosis: The Hidden Killer of Small Ruminants. Idris SM, Eltom KH, Okuni JB, Ojok L, Elmagzoub WA, El Wahed AA, Eltayeb E, Gameel AA.
Animals (Basel). 2021 Dec 21;12(1):12. doi: 10.3390/ani12010012.
PMID: 35011118 Review.
18.
Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review. Concerto C, Rodolico A, Ciancio A, Messina C, Natale A, Mineo L, Battaglia F, Aguglia E.
Int J Environ Res Public Health. 2021 Dec 25;19(1):199. doi: 10.3390/ijerph19010199.
PMID: 35010459 Review.
19.
Early Diagnosis of Multiple Sclerosis Using Swept-Source Optical Coherence Tomography and Convolutional Neural Networks Trained with Data Augmentation. López-Dorado A, Ortiz M, Satue M, Rodrigo MJ, Barea R, Sánchez-Morla EM, Cavaliere C, Rodríguez-Ascariz JM, Orduna-Hospital E, Boquete L, Garcia-Martin E.
Sensors (Basel). 2021 Dec 27;22(1):167. doi: 10.3390/s22010167.
PMID: 35009710
20.
The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. Ben-Shalom I, Karni A, Kolb H.
Int J Mol Sci. 2021 Dec 31;23(1):474. doi: 10.3390/ijms23010474.
PMID: 35008899 Review.
21.
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis. Scapoli C, Ziliotto N, Lunghi B, Menegatti E, Salvi F, Zamboni P, Baroni M, Mascoli F, Bernardi F, Marchetti G.
Int J Mol Sci. 2021 Dec 28;23(1):310. doi: 10.3390/ijms23010310.
PMID: 35008743
22.
T-Cell Response against Varicella Zoster Virus in Patients with Multiple Sclerosis during Relapse and Remission. Pérez-Saldívar M, Ordoñez G, Pineda B, Sotelo J, Martínez-Palomo A, Flores-Rivera J, Espinosa-Cantellano M.
Int J Mol Sci. 2021 Dec 28;23(1):298. doi: 10.3390/ijms23010298.
PMID: 35008726
23.
Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases. Cannon AS, Nagarkatti PS, Nagarkatti M.
Int J Mol Sci. 2021 Dec 28;23(1):288. doi: 10.3390/ijms23010288.
PMID: 35008717 Review.
24.
MiR-155: An Important Regulator of Neuroinflammation. Zingale VD, Gugliandolo A, Mazzon E.
Int J Mol Sci. 2021 Dec 22;23(1):90. doi: 10.3390/ijms23010090.
PMID: 35008513 Review.
25.
Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study. Haji Molla Rabi S, Shahmirzaei S, Sahraian MA, Kazemi Mozdabadi RS, Rezaei Aliabadi H, Gheini MR, Majidi F, Naser Moghadasi A.
Clin Neurol Neurosurg. 2021 May;204:106606. doi: 10.1016/j.clineuro.2021.106606. Epub 2021 Mar 20.
PMID: 33823399
26.
A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine. Krysko KM, Bischof A, Nourbakhsh B, Henry RG, Revirajan N, Manguinao M, Nguyen K, Akula A, Li Y, Waubant E.
Ann Clin Transl Neurol. 2021 Apr;8(4):811-824. doi: 10.1002/acn3.51325. Epub 2021 Mar 6.
PMID: 33675156 Free PMC article. Clinical Trial.
2022 January 11
1.
Pharmacology Focus: Multiple Sclerosis Treatment. Lemon M, Blanchette A, Severson T.
S D Med. 2021 Nov;74(11):538-539.
PMID: 35008142 No abstract available.
2.
Recombinant hepatitis B vaccine uptake and multiple sclerosis risk: A marginal structural modeling approach. Akhtar S, El-Muzaini H, Alroughani R.
Mult Scler Relat Disord. 2022 Jan 3;58:103487. doi: 10.1016/j.msard.2022.103487. Online ahead of print.
PMID: 35007824
3.
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Disanto G, Moccia M, Sacco R, Spiezia AL, Carotenuto A, Brescia Morra V, Gobbi C, Zecca C.
Mult Scler Relat Disord. 2022 Jan 3;58:103490. doi: 10.1016/j.msard.2022.103490. Online ahead of print.
PMID: 35007823
4.
The central vein sign is present in most infratentorial multiple sclerosis plaques. Gaitán MI, Paday Formenti ME, Calandri I, Ysrraelit MC, Yañez P, Correale J.
Mult Scler Relat Disord. 2022 Jan 3;58:103484. doi: 10.1016/j.msard.2021.103484. Online ahead of print.
PMID: 35007822
5.
Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Choudhury NA, Castrodad-Molina RM, Hutton GJ, Cuascut FX.
Mult Scler Relat Disord. 2022 Jan 4;58:103498. doi: 10.1016/j.msard.2022.103498. Online ahead of print.
PMID: 35007821
6.
Using Mnemonic in Management of Multiple Sclerosis. Toufic El Hussein M, Wong A.
J Neurosci Nurs. 2022 Feb 1;54(1):48-51. doi: 10.1097/JNN.0000000000000626.
PMID: 35007262
7.
IFN-β Causing Focal Segmental Glomerulosclerosis in a Multiple Sclerosis Patient-A Case Report. Al Armashi AR, Khan A, Somoza-Cano FJ, Patell K, Abuteer H, Ravakhah K.
Am J Ther. 2021 Jun 17. doi: 10.1097/MJT.0000000000001407. Online ahead of print.
PMID: 35006656 No abstract available.
8.
Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases. Meldolesi J.
Mol Biomed. 2021 Jun 20;2(1):18. doi: 10.1186/s43556-021-00040-5.
PMID: 35006460 Free PMC article. Review.
9.
Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Hada M, Mosholder AD, Leishear K, Perez-Vilar S.
Neurol Sci. 2022 Jan 10:1-11. doi: 10.1007/s10072-021-05846-3. Online ahead of print.
PMID: 35006442 Free PMC article. Review.
10.
Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review. Srikantharajah D, Lloyd ME, Kiely PDW.
Rheumatol Int. 2022 Jan 10. doi: 10.1007/s00296-021-05075-z. Online ahead of print.
PMID: 35006287 Review.
11.
Analysis of Multifocal Visual Evoked Potentials Using Artificial Intelligence Algorithms. Klistorner S, Eghtedari M, Graham SL, Klistorner A.
Transl Vis Sci Technol. 2022 Jan 3;11(1):10. doi: 10.1167/tvst.11.1.10.
PMID: 35006263
12.
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. Long M, Cross R, Calkwood J, Pondel M, Pai A, Ahmad H, Charles L, Elegbe A, Petersen A, Sheffield J, Javed A, Wolf D.
Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S9-S10. doi: 10.14309/01.ajg.0000798752.72296.f3.
PMID: 35006166
13.
P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial. Colombel JF, D’Haens G, Irving P, Petersen A, Chitkara D, Marta C, Chen T, Charles L, Danese S, Ghosh S.
Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S9. doi: 10.14309/01.ajg.0000798748.09138.3f.
PMID: 35006165
14.
The IL-2 – IL-2 receptor pathway: Key to understanding multiple sclerosis. Peerlings D, Mimpen M, Damoiseaux J.
J Transl Autoimmun. 2021 Sep 21;4:100123. doi: 10.1016/j.jtauto.2021.100123. eCollection 2021.
PMID: 35005590 Free PMC article. Review.
15.
Rho GTPase signaling in rheumatic diseases. Zeng R, Zhuo Z, Luo Y, Sha W, Chen H.
iScience. 2021 Dec 14;25(1):103620. doi: 10.1016/j.isci.2021.103620. eCollection 2022 Jan 21.
PMID: 35005558 Free PMC article. Review.
16.
Physical and Mental Health Comorbidities Among Adults With Multiple Sclerosis. Peterson MD, Lin P, Kamdar N, Marsack-Topolewski CN, Mahmoudi E.
Mayo Clin Proc Innov Qual Outcomes. 2021 Dec 23;6(1):55-68. doi: 10.1016/j.mayocpiqo.2021.11.004. eCollection 2022 Feb.
PMID: 35005438 Free PMC article.
17.
Vascular Dementia and Crosstalk Between the Complement and Coagulation Systems. Mossanen Parsi M, Duval C, Ariëns RAS.
Front Cardiovasc Med. 2021 Dec 23;8:803169. doi: 10.3389/fcvm.2021.803169. eCollection 2021.
PMID: 35004913 Free PMC article. Review.
18.
A Review on the Mechanism and Application of Keishibukuryogan. Tanaka K, Chiba K, Nara K.
Front Nutr. 2021 Dec 24;8:760918. doi: 10.3389/fnut.2021.760918. eCollection 2021.
PMID: 35004802 Free PMC article. Review.
19.
Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies. Zanin-Silva DC, Santana-Gonçalves M, Kawashima-Vasconcelos MY, Oliveira MC.
Front Med (Lausanne). 2021 Dec 22;8:788250. doi: 10.3389/fmed.2021.788250. eCollection 2021.
PMID: 35004754 Free PMC article. Review.
20.
Three-dimensional virtual histology of the cerebral cortex based on phase-contrast X-ray tomography. Eckermann M, van der Meer F, Cloetens P, Ruhwedel T, Möbius W, Stadelmann C, Salditt T.
Biomed Opt Express. 2021 Nov 15;12(12):7582-7598. doi: 10.1364/BOE.434885. eCollection 2021 Dec 1.
PMID: 35003854 Free PMC article.
21.
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, Merluzzo C, Baione V, Mazzochi L, Taglietti A, Pauri F, Frontoni M, Altieri M, Gaeta A, Antonelli G, Conte A, Mastroianni CM, Ciardi MR.
Mult Scler J Exp Transl Clin. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731. eCollection 2022 Jan-Mar.
PMID: 35003758 Free PMC article.
22.
Infections of scleroderma digital ulcers: A single center cohort retrospective study. Giuggioli D, Magnani L, Spinella A, Bajocchi G, Palermo A, Lumetti F, Cocchiara E, Salvarani C.
Dermatol Reports. 2021 Oct 5;13(3):9075. doi: 10.4081/dr.2021.9075. eCollection 2021 Nov 17.
PMID: 35003566 Free PMC article.
23.
Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis? Shang K, Cheng C, Qin C, Xiao J, Deng G, Bu BT, Xu SB, Tian DS.
Front Immunol. 2021 Dec 23;12:808420. doi: 10.3389/fimmu.2021.808420. eCollection 2021.
PMID: 35003138 Free PMC article.
24.
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP.
Front Immunol. 2021 Dec 24;12:763433. doi: 10.3389/fimmu.2021.763433. eCollection 2021.
PMID: 35003076 Free PMC article.
25.
The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation. Sandner L, Alteneder M, Zhu C, Hladik A, Högler S, Rica R, Van Greuningen LW, Sharif O, Sakaguchi S, Knapp S, Kenner L, Trauner M, Ellmeier W, Boucheron N.
Front Immunol. 2021 Dec 21;12:750466. doi: 10.3389/fimmu.2021.750466. eCollection 2021.
PMID: 35003062 Free PMC article.
26.
Editorial: Nuclear Receptors and Coregulators in Metabolism and Immunity. Fan R, Pineda-Torra I, Venteclef N.
Front Endocrinol (Lausanne). 2021 Dec 24;12:828635. doi: 10.3389/fendo.2021.828635. eCollection 2021.
PMID: 35002987 Free PMC article. No abstract available.
27.
Comparative Proteomic Profiling Identifies Reciprocal Expression of Mitochondrial Proteins Between White and Gray Matter Lesions From Multiple Sclerosis Brains. Rai NK, Singh V, Li L, Willard B, Tripathi A, Dutta R.
Front Neurol. 2021 Dec 24;12:779003. doi: 10.3389/fneur.2021.779003. eCollection 2021.
PMID: 35002930 Free PMC article.
28.
Improving Health of People With Multiple Sclerosis From a Multicenter Randomized Controlled Study in Parallel Groups: Preliminary Results on the Efficacy of a Mindfulness Intervention and Intention Implementation Associated With a Physical Activity Program. Torkhani E, Dematte E, Slawinski J, Csillik A, Gay MC, Bensmaïl D, Heinzlef O, de Marco G.
Front Psychol. 2021 Dec 24;12:767784. doi: 10.3389/fpsyg.2021.767784. eCollection 2021.
PMID: 35002857 Free PMC article.
29.
Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone®. Lipsky P, Vallano PT, Smith J, Owens W, Snider D, Bandaru V, Sun Y, Wallingford R, Duncan J, Lewis J, Southall J, Ansari A, Li H.
Front Pharmacol. 2021 Dec 24;12:760726. doi: 10.3389/fphar.2021.760726. eCollection 2021.
PMID: 35002702 Free PMC article.
30.
Proteinopathies as Hallmarks of Impaired Gene Expression, Proteostasis and Mitochondrial Function in Amyotrophic Lateral Sclerosis. Benson BC, Shaw PJ, Azzouz M, Highley JR, Hautbergue GM.
Front Neurosci. 2021 Dec 23;15:783624. doi: 10.3389/fnins.2021.783624. eCollection 2021.
PMID: 35002606 Free PMC article. Review.
31.
Coexistence of Autoantibodies and Other Autoimmune Diseases with Multiple Sclerosis and Related Disorders – Experience from the Mangalore Demyelinating Disease Registry (MANDDIR). Malli C, Pandit L, D’Çunha MA, Sudhir A.
Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):740-744. doi: 10.4103/aian.AIAN_170_21. Epub 2021 Jun 22.
PMID: 35002133 Free PMC article.
32.
Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders. Patil VA, Kamat SN, Lalkaka JA, Singhal B.
Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):732-739. doi: 10.4103/aian.AIAN_167_21. Epub 2021 Jun 22.
PMID: 35002132 Free PMC article.
33.
A Narrative Review Study on the Effects of Obesity and Bariatric Surgery on Multiple Sclerosis. Abna Z, Fazeli SA, Mirhashemi S, Mirzaei K, Emami F, Jamili S, Dehghani R.
Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):664-667. doi: 10.4103/aian.AIAN_235_21. Epub 2021 Oct 14.
PMID: 35002123 Free PMC article.
34.
Myelination synchronizes cortical oscillations by consolidating parvalbumin-mediated phasic inhibition. Dubey M, Pascual-Garcia M, Helmes K, Wever DD, Hamada MS, Kushner SA, Kole MHP.
Elife. 2022 Jan 10;11:e73827. doi: 10.7554/eLife.73827. Online ahead of print.
PMID: 35001871
35.
Multiple variants of soluble CD146 are involved in Systemic Sclerosis: identification of a novel pro-fibrotic factor. Nollet M, Bachelier R, Joshkon A, Traboulsi W, Mahieux A, Moyon A, Muller A, Somasundaram I, Simoncini S, Peiretti F, Leroyer AS, Guillet B, Granel B, Dignat-George F, Bardin N, Foucault-Bertaud A, Blot-Chabaud M.
Arthritis Rheumatol. 2022 Jan 9. doi: 10.1002/art.42063. Online ahead of print.
PMID: 35001552
36.
Paeonol Ameliorates Cuprizone-Induced Hippocampal Demyelination and Cognitive Deficits through Inhibition of Oxidative and Inflammatory Events. Pourmohammadi S, Roghani M, Kiasalari Z, Khalili M.
J Mol Neurosci. 2022 Jan 10. doi: 10.1007/s12031-021-01951-2. Online ahead of print.
PMID: 35001353
37.
Atypical presentations and course of JC virus infection. Chatterton S, Dwyer L, Thomson C, Plit M, Longmuir H, Chaganti J, Barnett Y, Brew B.
J Neurovirol. 2022 Jan 9. doi: 10.1007/s13365-021-01031-6. Online ahead of print.
PMID: 35001250
38.
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. Peters KB, Affronti ML, Woodring S, Lipp E, Healy P, Herndon JE 2nd, Miller ES, Freeman MW, Randazzo DM, Desjardins A, Friedman HS.
Support Care Cancer. 2022 Jan 10. doi: 10.1007/s00520-021-06738-0. Online ahead of print.
PMID: 35001215
39.
Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Cobo-Calvo A, Zabalza A, Río J, Arrambide G, Otero-Romero S, Tagliani P, Cárdenas-Robledo S, Castillo M, Espejo C, Rodriguez M, Carbonell P, Rodríguez B, Midaglia L, Vidal-Jordana Á, Tur C, Galan I, Castillo J, Comabella M, Nos C, Auger C, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J.
J Neurol. 2022 Jan 10. doi: 10.1007/s00415-021-10958-z. Online ahead of print.
PMID: 35001198
40.
Clinically Isolated Brainstem Progressive Multifocal Leukoencephalopathy: Diagnostic Challenges. Khan F, Sharma N, Ud Din M, Akabalu IG.
Am J Case Rep. 2022 Jan 10;23:e935019. doi: 10.12659/AJCR.935019.
PMID: 35001072
41.
[NEUROPSYCHOLOGICAL ANALYSIS OF DISORDERS OF HIGHER MENTAL FUNCTIONS IN PATIENTS WITH DIFFERENT TYPES OF MULTIPLE SCLEROSIS]. Pryvalova N, Negreba T, Sukhorukov V, Bovt Y, Zabrodina L.
Georgian Med News. 2021 Dec;(321):51-57.
PMID: 35000908 Russian.
42.
Global survey on disruption and mitigation of neurological services during COVID-19: the perspective of global international neurological patients and scientific associations. Triki CC, Leonardi M, Mallouli SZ, Cacciatore M, Karlshoej KC, Magnani FG, Newton CR, Pilotto A, Saylor D, Westenberg E, Walsh D, Winkler AS, Thakur KT, Okubadejo NU, Garcia-Azorin D.
J Neurol. 2022 Jan;269(1):26-38. doi: 10.1007/s00415-021-10641-3. Epub 2021 Jun 11.
PMID: 34117527 Free PMC article.
43.
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, Rodrigues PM, Zhuravleva E, O’Rourke CJ, Hijona E, Jimenez-Agüero R, Riaño I, Landa A, La Casta A, Zaki MYW, Munoz-Garrido P, Azkargorta M, Elortza F, Vogel A, Schabbauer G, Aspichueta P, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ.
Gut. 2021 Jul;70(7):1345-1361. doi: 10.1136/gutjnl-2019-319227. Epub 2020 Sep 9.
PMID: 32907830 Free PMC article.